 Interleukin-12
"Interleukin-12" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-12 is a 70 kDa protein that is composed of covalently linked 40 kDa and 35 kDa subunits. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells and plays a role in the stimulation of INTERFERON-GAMMA production by T-LYMPHOCYTES and NATURAL KILLER CELLS.
| Descriptor ID |
D018664
|
| MeSH Number(s) |
D12.644.276.374.465.512 D12.776.467.374.465.512 D23.529.374.465.512
|
| Concept/Terms |
Interleukin-12- Interleukin-12
- Edodekin Alfa
- IL 12
- Natural Killer Cell Stimulatory Factor
- IL-12 p70
- IL12
- Interleukin 12
- Interleukin-12 p70
- Interleukin 12 p70
- p70, Interleukin-12
- Cytotoxic Lymphocyte Maturation Factor
- IL-12
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-12".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-12".
This graph shows the total number of publications written about "Interleukin-12" by people in this website by year, and whether "Interleukin-12" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 1 | 2 | | 1997 | 2 | 0 | 2 | | 1999 | 4 | 1 | 5 | | 2000 | 1 | 2 | 3 | | 2001 | 3 | 4 | 7 | | 2002 | 2 | 1 | 3 | | 2003 | 5 | 1 | 6 | | 2004 | 4 | 2 | 6 | | 2005 | 5 | 4 | 9 | | 2006 | 0 | 2 | 2 | | 2007 | 0 | 3 | 3 | | 2008 | 2 | 2 | 4 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 2 | 3 | | 2011 | 1 | 3 | 4 | | 2012 | 2 | 4 | 6 | | 2013 | 1 | 2 | 3 | | 2014 | 3 | 0 | 3 | | 2018 | 0 | 2 | 2 | | 2019 | 1 | 1 | 2 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-12" by people in Profiles.
-
Mansurov A, Ishihara J, Hosseinchi P, Potin L, Marchell TM, Ishihara A, Williford JM, Alpar AT, Raczy MM, Gray LT, Swartz MA, Hubbell JA. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat Biomed Eng. 2020 05; 4(5):531-543.
-
Trujillo JA, Luke JJ, Zha Y, Segal JP, Ritterhouse LL, Spranger S, Matijevich K, Gajewski TF. Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 11 08; 7(1):295.
-
Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, Triggs DA, Reardon DA, Wen P, Stopa BM, Naik A, Rudnick J, Hu JL, Kumthekar P, Yamini B, Buck JY, Demars N, Barrett JA, Gelb AB, Zhou J, Lebel F, Cooper LJN. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019 08 14; 11(505).
-
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661.
-
Stein MM, Hrusch CL, Sperling AI, Ober C. Effects of an Fc?RIIA polymorphism on leukocyte gene expression and cytokine responses to anti-CD3 and anti-CD28 antibodies. Genes Immun. 2019 07; 20(6):462-472.
-
Roth JC, Cassady KA, Cody JJ, Parker JN, Price KH, Coleman JM, Peggins JO, Noker PE, Powers NW, Grimes SD, Carroll SL, Gillespie GY, Whitley RJ, Markert JM. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev. 2014 Mar; 25(1):16-27.
-
Leonardi CL, Gordon KB. New and emerging therapies in psoriasis. Semin Cutan Med Surg. 2014 Mar; 33(2 Suppl 2):S37-41.
-
Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B, Tobias AL, Han Y, Zhang L, Moon KS, Lesniak MS. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther. 2014 Jan; 21(1):38-44.
-
Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M, Chimenti S, Costanzo A. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013 Aug; 169(2):458-63.
-
Whitley RJ, Markert JM. Viral therapy of glioblastoma multiforme. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):11672-3.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|